CorMedix to Expand Pipeline After February Melinta Deal, Q2 Rezzayo Data Due
CorMedix will leverage its February 2026 Melinta deal to expand from one to multiple anti-infective products over the next 18 months. The company expects to report top-line Q2 2026 data for its lead candidate Rezzayo in June, potentially triggering Phase III planning.
1. Investor Day Key Takeaways
During its February 2026 Investor Day, CorMedix outlined strategic priorities to evolve from a single-product focus to a diversified pharmaceutical company, emphasizing anti-infective therapies and planning market launches through 2027.
2. Melinta Transaction and Pipeline Expansion
CorMedix executed a Melinta strategic asset purchase in February 2026, acquiring two antibiotic candidates and related manufacturing capabilities; management forecasts these additions will complement its existing pipeline and drive revenue growth starting in 2027.
3. Upcoming Rezzayo Q2 Data
The company anticipates releasing top-line results for Rezzayo’s Phase II trial in June 2026; positive outcomes could enable Phase III initiation later in the year and bolster its valuation ahead of potential licensing or partnership discussions.